VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma.

被引：0
|
作者：
Alexaman, R [1 ]
Wang, LM [1 ]
Weber, DM [1 ]
Delasalle, KB [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
210
引用
收藏
页码：64A / 64A
页数：1
相关论文
共 50 条
  • [31] Thalidomide and dexamethasone combination for refractory multiple myeloma.
    Galani, E
    Grigoraki, V
    Kiamouris, C
    Samantas, E
    Economou, O
    Papdimitriou, C
    Gika, D
    Anagnostopoulos, N
    Dimopoulos, M
    ANNALS OF ONCOLOGY, 2000, 11 : 96 - 96
  • [32] Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients
    Ciolli, S
    Leoni, F
    Gigli, F
    Rigacci, L
    Bosi, A
    LEUKEMIA & LYMPHOMA, 2006, 47 (01) : 171 - 173
  • [33] EFFECT OF THALIDOMIDE-DEXAMETHASONE THERAPY ON BONE MARROW ANGIOGENESIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    Ladeb, S.
    Mrad, K.
    Abdelkefi, A.
    Torjemane, L.
    Safra, I.
    Hdiji, S.
    Ben Romdhane, N.
    Mdhaffer, M.
    El Omri, H.
    Ben Othman, T.
    Ben Romdhane, K.
    Ben Abdeladhim, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 512 - 512
  • [34] Cyclophosphamide, thalidomide and dexamethasone (CTD) as initial therapy for newly diagnosed multiple myeloma patients.
    Chavez, Jule Franve Vasquez
    Mendoza, Rossana Esther Ruiz
    Llerena, Karina Mayra Aliaga
    Valencia, Fernando
    Enriquez, Daniel
    Palacios, Victor
    Casanova, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
    Jimenez-Zepeda, Victor Hugo
    Dominguez-Martinez, Virginia Jeanet
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (03) : 239 - 244
  • [36] Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma
    Gay, Francesca
    Hayman, Suzanne
    Lacy, Martha Q.
    Buadi, Francis
    Gertz, Morie A.
    Kumar, Shaji
    Dispenzieri, Angela
    Mikhael, Joseph R.
    Bergsagel, Leif
    Dingli, David
    Reeder, Craig B.
    Lust, John A.
    Russel, Stephen
    Roj, Vivek
    Zeldenrust, Steven R.
    Witzig, Thomas E.
    Fonseca, Rafael
    Kyle, Robert
    Greipp, Philip R.
    Stewart, A. Keith
    Rajkumar, S. Vincent
    BLOOD, 2009, 114 (22) : 1494 - 1495
  • [37] Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma.
    Palumbo, A
    Bertola, A
    Musto, P
    Nunzi, M
    De Stefano, V
    Callea, V
    Rotoli, B
    Petti, MC
    Caravita, T
    Lauta, VM
    Patti, C
    Bringhen, S
    Cavallo, F
    Falco, P
    Carella, AM
    Liberati, AM
    Boccadoro, M
    BLOOD, 2003, 102 (11) : 148A - 148A
  • [38] Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) as induction treatment for newly diagnosed Multiple Myeloma (MM) is associated with a lower rate of Second Primary Malignancies (SPMs) compared to Thalidomide-Dexamethasone (TD)
    Brioli, A.
    Pezzi, A.
    Muegge, L-O
    Derudas, D.
    Petti, M. C.
    Zannetti, B. A.
    Ferrara, F.
    Rocchi, S.
    Nobile, F.
    Baraldi, A.
    Musto, P.
    Lanza, F.
    Mancuso, K.
    Canepa, L.
    Catalano, L.
    Lazzaro, A.
    Pinotti, G.
    Boccadoro, M.
    Hochhaus, A.
    Cavo, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 69 - 69
  • [39] Long-term treatment of newly-diagnosed multiple myeloma with low-dose thalidomide, dexamethasone and zoledronate (TDZ).
    Klueppelberg, U
    Shapira, I
    Chen, L
    Aloba, MC
    Smith, E
    Palanisamy, N
    Schmidt, J
    Moezi, M
    Batuman, O
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 608S - 608S
  • [40] VTD (VELCADE, THALIDOMIDE, DEXAMETHASON) REPRESENTS AN ACTIVE INDUCTION REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA
    Drach, W.
    Odelga, V.
    Ackermann, J.
    Sagaster, V.
    Kaufmann, H.
    Worel, N.
    Rabitsch, W.
    Kalhs, P.
    Zielinski, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 87 - 88
12345